R&D / Collaborative Research
We pride ourselves on developing strong relationships with research and development partners in internationally recognized research institutes. These partnerships play a large role in the development of our product pipeline.
If you are interested in collaborating with HRA Pharma, please contact us at email@example.com.
Our collaborative research activities include:
US National Institutes of Health
HRA Pharma has successfully entered into two Collaborative Research and Development Agreements with the US National Institute of Child Health and Human Development, a remarkable accomplishment for a small European pharmaceutical company. The first, signed in 2001 and renewed in 2005, relates to the clinical development of CDB-2914 (ella® / ellaOne®, UPA). The second, signed in 2006, covers the development of HRA 052015 for Cushing's syndrome secondary to ectopic ACTH secretion.
The Population Council is an international, not-for-profit, non-governmental organization that conducts biomedical, social science, and public health research. HRA Pharma has been working with the Council on various projects to develop innovative contraceptive technologies. One of these projects involves HRA Pharma's product UPA, first-in-class, orally active selective progesterone receptor modulator being developed to provide continuous contraception via novel delivery systems.
Gynuity Health Projects
Gynuity Health Projects, a non governmental, not-for-profit research and technical assistance organization in reproductive health, has developed multiple research programs on misoprostol, a drug currently registered in over 60 countries for the treatment and prevention of certain types of gastric ulcers. HRA Pharma is working with Gynuity on the development of misoprostol as a safe, effective and acceptable non-surgical alternative for the treatment of incomplete abortion as well as an additional tool in the prevention and treatment of post-partum hemorrhage.
Collaborative group for Adrenocortical Carcinoma Therapy (COACT)
COACT is an international group of adrenal diseases specialists who work together on the optimization of the management and treatment of adrenal cortical carcinoma, an extremely rare condition. In 2004, HRA Pharma entered into collaboration with this group in order to support a prospective open label pharmacokinetic study on Lysodren (mitotane, 500mg). This study is an ancillary study to the First International Randomized trial in Metastatic Adrenocortical Cancer Treatment (FIRM-ACT) study, the largest trial ever performed in this rare disease.